CCAP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CCAP is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is essentially flat near $13.60, the technical setup is neutral, options sentiment is mildly balanced, and recent fundamentals have weakened. Because there is no strong proprietary buy signal and earnings are imminent, the better call is to hold and wait for clearer confirmation rather than buy immediately.
CCAP is trading around 13.60, essentially at its pivot level of 13.581, which signals a neutral near-term setup. RSI_6 is 49.959, showing no clear overbought or oversold condition. MACD histogram is slightly positive at 0.0368 but is contracting, which suggests momentum is fading rather than accelerating. Moving averages are converging, reinforcing a sideways trend rather than a decisive uptrend. Resistance is near 13.967 and 14.206, while support sits at 13.196 and 12.957. Overall, the chart does not show a strong entry signal.
["Gross margin improved to 87.37% in Q4 2025, indicating solid operating efficiency.", "Analyst Keefe Bruyette still keeps an Outperform rating with a $15 target, above the current price.", "The stock is trading below that $15 target and near the lower end of recent analyst targets.", "Historically favorable credit and operating metrics versus peers were noted by B. Riley.", "Next earnings are scheduled for 2026-05-13 after hours, which could act as an event-driven catalyst."]
["Recent quarterly revenue fell 8.66% year over year.", "Net income declined 15.02% year over year.", "EPS dropped 14.81% year over year.", "B. Riley initiated coverage with a Neutral rating and said recent performance has been less compelling.", "Wells Fargo lowered its price target to $13 and maintained only an Equal Weight rating.", "No recent news catalysts were available in the past week.", "No meaningful hedge fund, insider, or congress trading activity was reported."]
In Q4 2025, CCAP showed weaker top-line and bottom-line performance. Revenue declined to 32.823 million, down 8.66% year over year. Net income fell 15.02% year over year to 8.49 million, and EPS dropped 14.81% year over year to 0.23. The one positive was gross margin, which improved to 87.37%, up 1.10% year over year. Overall, the latest quarter shows profitability resilience but slowing growth.
Analyst sentiment is mixed to cautious. Keefe Bruyette lowered its target from $15.50 to $15 while keeping an Outperform rating. B. Riley initiated coverage at Neutral with a $13.50 target and said the stock is appropriately valued. Wells Fargo cut its target from $14 to $13 and kept an Equal Weight rating, noting cautious optimism around a possible fee and dividend revisit. The Wall Street view is split, but the tone has become more conservative overall, with upside now looking limited near the current price.
